Antithrombotic therapy in patients with COVID-19: indications, pharmacotherapy and controversy.
Publication
, Journal Article
Wang, D; Leo, C; Liu, L; Huang, L; Huang, L; Lu, Y
Published in: Stroke Vasc Neurol
August 2023
Duke Scholars
Published In
Stroke Vasc Neurol
DOI
EISSN
2059-8696
Publication Date
August 2023
Volume
8
Issue
4
Start / End Page
263 / 265
Location
England
Related Subject Headings
- Platelet Aggregation Inhibitors
- Humans
- Fibrinolytic Agents
- COVID-19
- Anticoagulants
Citation
APA
Chicago
ICMJE
MLA
NLM
Wang, D., Leo, C., Liu, L., Huang, L., & Lu, Y. (2023). Antithrombotic therapy in patients with COVID-19: indications, pharmacotherapy and controversy. Stroke Vasc Neurol, 8(4), 263–265. https://doi.org/10.1136/svn-2023-002321
Wang, David, Christopher Leo, Liping Liu, Li Huang, Lisa Huang, and Yun Lu. “Antithrombotic therapy in patients with COVID-19: indications, pharmacotherapy and controversy.” Stroke Vasc Neurol 8, no. 4 (August 2023): 263–65. https://doi.org/10.1136/svn-2023-002321.
Wang D, Leo C, Liu L, Huang L, Lu Y. Antithrombotic therapy in patients with COVID-19: indications, pharmacotherapy and controversy. Stroke Vasc Neurol. 2023 Aug;8(4):263–5.
Wang, David, et al. “Antithrombotic therapy in patients with COVID-19: indications, pharmacotherapy and controversy.” Stroke Vasc Neurol, vol. 8, no. 4, Aug. 2023, pp. 263–65. Pubmed, doi:10.1136/svn-2023-002321.
Wang D, Leo C, Liu L, Huang L, Lu Y. Antithrombotic therapy in patients with COVID-19: indications, pharmacotherapy and controversy. Stroke Vasc Neurol. 2023 Aug;8(4):263–265.
Published In
Stroke Vasc Neurol
DOI
EISSN
2059-8696
Publication Date
August 2023
Volume
8
Issue
4
Start / End Page
263 / 265
Location
England
Related Subject Headings
- Platelet Aggregation Inhibitors
- Humans
- Fibrinolytic Agents
- COVID-19
- Anticoagulants